SOHO Annual Meeting 2022

The Tenth Annual Meeting of the Society of Hematologic Oncology took place from September 28 to October 1 in Houston, Texas, and focused on how to apply the latest research on hematological malignancies in clinical practice. This year’s meeting featured meet-the-professor sessions, plenary lectures, expert sessions, oral abstract presentations, and more related to the meeting’s theme, Novel Immunotherapies in Hematologic Malignancies: BiTEs, TRiTEs, and Cellular Therapies. Find the highlights of the sessions that are most relevant to oncology nurses, including those with a focus on the latest treatment strategies for graft-versus-host disease.

image header
Advertisement
Acute GVHD Raises Risk of Transplant-Related Mortality in Certain Patients
Acute graft-versus-host disease (GVHD) may increase the risk of transplant-related mortality by sevenfold in certain patients. New research presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) showed acute GVHD of grade 3 or higher independently raised the risk of first-year transplant-related mortality in patients who developed cytokine release syndrome after haploidentical hematopoietic stem-cell transplantation (HSCT) with posttransplant cyclophosphamide. ...
Advertisement
Cecilia BrownConferences | September 28, 2022
Pre-transplant clofarabine and total body irradiation led to a 22% GVHD relapse-free survival rate in patients with leukemia.
Read More
Cecilia BrownConferences | September 28, 2022
DSA did not lead to graft failure or impact the GVHD incidence in patients who received haploidentical HSCT.
Cecilia BrownConferences | September 28, 2022
Extracorporeal photopheresis, a treatment for GVHD, may function by inducing formation of neutrophil extracellular traps.
Cecilia BrownConferences | September 30, 2022
The cumulative incidence of GVHD was higher in patients who received a low CD3-positive T-cell dose during transplant.
Cecilia BrownConferences | September 30, 2022
There are several risk factors for chronic GVHD in patients who received allogeneic haploidentical HSCT.
Cecilia BrownConferences | September 30, 2022
Most patients who received allogeneic HSCT with omidubicel did not develop chronic graft-versus-host disease (GVHD).
Advertisement
Advertisement